SCHEMBL6715728

SCHEMBL6715728

COC(=O)c1ccccc1NC(=O)C(N)c1ccccc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.60
TDP1 Q9NUW8 1/20 0.60
KMT2A Q03164 3/20 0.56
GAA P10253 4/20 0.55
KDM4E B2RXH2 9/20 0.55
ALDH1A1 P00352 8/20 0.55
HPGD P15428 4/20 0.55
HTT P42858 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
POLB P06746 1/20 0.53
ATM Q13315 1/20 0.53
MAPT P10636 4/20 0.53
ALOX15 P16050 2/20 0.53
HSD17B10 Q99714 3/20 0.51
MAPK1 P28482 1/20 0.51
MAPK10 P53779 1/20 0.51
MEN1 O00255 2/20 0.50
LMNA P02545 2/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
ALOX12 P18054 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28304178 1.00 TSHR (0.60) TSHRTDP1KMT2AGAAKDM4E
SCHEMBL3860229 0.84 TSHR (0.66) TSHRTDP1KMT2AGAAKDM4E
SCHEMBL27752376 0.83 KDM4E (0.54) KMT2AGAAKDM4EALDH1A1HPGD
SCHEMBL25904137 0.83 TSHR (0.65) TSHRTDP1KMT2AGAAKDM4E
SCHEMBL28618843 0.81 KDM4E (0.56) TSHRTDP1KMT2AGAAKDM4E
SCHEMBL28302853 0.81 MAPT (0.63) TSHRTDP1KMT2AGAAALDH1A1
SCHEMBL6714273 0.81 MAPT (0.63) TSHRTDP1KMT2AGAAALDH1A1
SCHEMBL6821760 0.80 TSHR (0.58) TSHRTDP1KMT2AGAAKDM4E
SCHEMBL5928724 0.80 TSHR (0.68) TSHRTDP1KMT2AGAAKDM4E
SCHEMBL6821860 0.79 TSHR (0.56) TSHRTDP1KMT2AGAAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110041285-B Preparation method of 2, 4, 5-trisubstituted oxazole compound 大连理工大学 2021-08-20 CN disclosed
CN-110041285-A The preparation method of 2,4,5- of one kind, tri- substituted oxazoline class compound 大连理工大学 2019-07-23 CN disclosed
US-20040152740-A1 Arylglycine derivatives for use as glycine transport inhibitors NPS ALLELIX CORPORATION (CA) 2004-08-05 US disclosed
WO-2004022534-A1 ARYLGLYCINE DERIVATIVES FOR USE AS GLYCINE TRANSPORT INHIBITORS NPS ALLELIX CORP. (CA) 2004-03-18 WO disclosed
WO-2004022534-A1 ARYLGLYCINE DERIVATIVES FOR USE AS GLYCINE TRANSPORT INHIBITORS NPS ALLELIX CORP. (CA) 2004-03-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152740-A1 Arylglycine derivatives for use as glycine transport inhibitors SLC1A2, SLC6A7, SLC1A1 TSHR 3060/4885TDP1 1032/4885KMT2A 2020/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.